Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
58 Results for "
instability
" in MedChemExpress (MCE) Product Catalog:
Products (58)
58 Results for "instability" in MCE Product Catalog:
Cat. No.: HY-184293
PROTAC ATR degrader-4 is a PROTAC-based ATR kinase degrader, with a DC50 of 6.18 μM and a Dmax of 71.42% in LoVo cells. PROTAC ATR degrader-4 downregulates ATR protein expression, inducing nuclear envelope rupture, genomic instability, DNA damage and apoptosis. PROTAC ATR degrader-4 exhibits anti-tumor activity in xenograft tumor mouse models and can be used for the research of atm-deficient cancers .
Cat. No.: HY-182313
Target:
Research Areas:
WRN-IN-25 is an allosteric Werner syndrome helicase (WRN) inhibitor with an IC50 of 15 nM and a Kd of 54 nM. WRN-IN-25 induces DNA damage, reduces cell viability, and exhibits synthetic lethality in WRN-driven high microsatellite instability cancer cells. WRN-IN-25 can be used in research related to microsatellite instability cancers .
Research Areas:
Nitrosulfathiazole (Nisulfazole; p-Nitrosulfathiazole) is a sulfonamide antibacterial agent and also a key chemical intermediate for the hematotoxicity of Chloramphenicol (HY-B0239). Nitrosulfathiazole induces DNA helix instability, strand breakage and aplastic anemia. Nitrosulfathiazole can be used in research related to bacterial infections and aplastic anemia .
Cat. No.: HY-184704
Target:
Research Areas:
BChE-IN-52 is a selective butyrylcholinesterase (BChE) inhibitor with an IC50 of 0.25 μM against horse serum-derived BChE. BChE-IN-52 exhibits weak antioxidant activity, shows no mutagenicity, and displays photochemical instability under UV irradiation. BChE-IN-52 can be used in the research of Alzheimer's disease .
Cat. No.: HY-182391
CAS No.: 3084702-28-0
MKI-3 is a selective microtubule-associated serine/threonine kinase-like (MASTL) inhibitor with an IC50 of 5.72 nM and a Kd of 1.89 nM. MKI-3 disrupts the MASTL-ENSA-Aurora A signaling axis. MKI-3 induces chromosomal instability, mitotic catastrophe and apoptosis (apoptosis) in cancer cells. MKI-3 is applicable to research related to triple-negative breast cancer .
Cat. No.: HY-168555A
YJ1206 TFA is an orally active selective CDK12/CDK13 PROTAC degrader. YJ1206 TFA induces DNA damage and genomic instability, activates the AKT pathway, and triggers apoptosis. YJ1206 TFA reduces tumor cell viability, inhibits tumor growth, and attenuates tumor cell dissemination. YJ1206 TFA is applicable to research related to prostate cancer and high-grade serous tubo-ovarian cancer .
Cat. No.: HY-101566R
CAS No.: 1876467-74-1
Synonyms: BAY 1895344 (Standard)
Target:
Research Areas:
Elimusertib (Standard) is the analytical standard of Elimusertib (HY-101566). This product is intended for research and analytical applications. Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib has anti-tumor activity . Elimusertib can be used for the research of solid tumors and lymphomas .
Cat. No.: HY-119475
CAS No.: 56302-13-7
Target:
Research Areas:
Satranidazole is an orally active insecticide and antimicrobial agent with high electron affinity. Satranidazole forms reduced nitro intermediates, which interact with DNA, causing helix instability, strand breakage and release of thymidine derivatives. Satranidazole exhibits antitrichomonal activity against Trichomonas vaginalis and Trichomonas foetus, and antiamoebic activity in rodent models of hepatic amoebiasis and caecal amoebiasis. Satranidazole inhibits the replication of bacteriophage φX174 DNA. Satranidazole can be used in research related to caecal amoebiasis, trichomoniasis and anaerobic bacterial infections .
Cat. No.: HY-181562
CAS No.: 3113010-46-8
Target:
Research Areas:
WRN-IN-24 is an orally active allosteric covalent Werner syndrome helicase (WRN) inhibitor with an IC50 of 201 nM. WRN-IN-24 binds to a novel allosteric cavity, forms an additional hydrogen bond with K894, and functionally inhibits WRN activity. WRN-IN-24 inhibits colorectal cancer cells proliferation and exerts dose-dependent antitumor activity in xenograft mouse models. WRN-IN-24 can be used for the research of microsatellite instability-high cancers, including colorectal cancer .
Cat. No.: HY-119475S
Cat. No.: HY-183610
CAS No.: 3059172-54-9
Target:
Research Areas:
WRN-IN-26 is an orally active Werner syndrome helicase (WRN) inhibitor with a human Ki value of 58.7 μM and an IC50 value of 0.026 μM. WRN-IN-26 selectively targets the cysteine residues of WRN. WRN-IN-26 induces the expression of p21 protein in MSI-H tumor cells. WRN-IN-26 inhibits the growth of MSI-H tumor cells and exhibits potent in vivo efficacy in MSI-H xenograft tumor models. WRN-IN-26 can be used for the research of microsatellite instability-high (MSI-H) cancers .
Cat. No.: HY-181840
CAS No.: 1846587-13-0
Target:
Research Areas:
MU262 is a MUS81 inhibitor with an IC50 value of 0.87 μM. MU262 directly inhibits the catalytic activity of MUS81 without interfering with DNA binding, induces genomic instability in tumor cells, and specifically inhibits the HR/BIR repair pathway. The combination of MU262 with Cisplatin (HY-17394) significantly enhances the chemotherapeutic killing effect. MU262 serves as a chemical biology tool for studying MUS81 function, and also acts as a lead compound for the development of anticancer therapies that exploit DNA repair defects in cancer cells .
Cat. No.: HY-109566R
CAS No.: 2089288-03-7
Synonyms: AZD1390 (Standard)
Research Areas:
Elrelesertib (Standard) (AZD1390 (Standard)) is the analytical standard of Elrelesertib (AZD1390) (HY-109566). This product is intended for research and analytical applications. Elrelesertib (AZD1390) is an orally active, brain-penetrant ATM kinase inhibitor with IC50 values of 0.78 nM. Elrelesertib blocks ATM-dependent DNA damage response, inhibits ATM autophosphorylation and downstream Chk2, Rad50 phosphorylation, and accumulates at DNA breaks. Elrelesertib acts as a radiosensitizer, induces apoptosis, genomic instability, G2-M cell cycle arrest, ROS elevation, and mitochondrial membrane potential alteration. Elrelesertib has low efflux liability against P-gp and BCRP. Elrelesertib can be used for the research of central nervous system malignancies, glioblastoma multiforme, glioma, lung cancer brain metastases, and breast cancer .
Cat. No.: HY-182037
Target:
Research Areas:
Multi-target kinase-IN-9 is a multi-target enzyme inhibitor with antiproliferative and antiangiogenic activities, and exhibits remarkable selectivity against hepatocellular carcinoma cells. By broadly binding to the active sites or ATP-binding regions of multiple key enzymes including DNA polymerase β, Pyruvate Kinase M2 (PKM2), Multi-target kinase-IN-9 comprehensively disrupts DNA repair and replication, glycolysis, chromatin dynamics and transcriptional programs, and blocks the self-renewal of cancer stem cells. Multi-target kinase-IN-9 induces genomic instability, lysosomal dysfunction and autophagic flux impairment, thereby triggering tumor cell death, effectively inhibiting tumor proliferation, invasion, metastasis and angiogenesis, and significantly reducing tumor volume in xenograft models. Multi-target kinase-IN-9 is applicable to hepatocellular carcinoma-related research .
Cat. No.: HY-L085
2,199 compounds
Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.
MCE offers a unique collection of 2,199 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.
Cat. No.: HY-L034
7,771 compounds
Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.
MCE Anti-Aging Compound Library contains 7,771 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.
Cat. No.: HY-112817A
Synonyms: 8-Oxo-Deoxyguanosine triphosphate trisodium
8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) trisodium solution (100mM) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP trisodium solution (100mM) acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP trisodium solution (100mM) causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP trisodium solution (100mM) in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP trisodium solution (100mM) is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
